NZYM B Novozymes A/S Class B

Major shareholder announcement

Major shareholder announcement

Pursuant to Section 30 of the Danish Capital Markets Act, Novonesis hereby announces that BlackRock, Inc. has notified Novonesis of the following status relating to the position of share capital attached to shares and share capital through financial instruments.

Per October 22, 2024, BlackRock, Inc. has adjusted its holding of shares to an equivalent of 23,548,644 shares, corresponding to 5.02% (previously 4.92%) of the total share capital attached to shares. The combined total of share capital attached to shares and share capital through financial instruments is 5.05% (previously 5.01%).

Attachments



EN
23/10/2024

Underlying

NZYM BNovozymes A/S Class B

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Novozymes A/S Class B

 PRESS RELEASE
Free
NZYM B Novozymes A/S C...

Major shareholder announcement

Major shareholder announcement Pursuant to Section 30 of the Danish Capital Markets Act, Novonesis hereby announces that BlackRock, Inc. has notified Novonesis of the following status relating to the position of share capital attached to shares and share capital through financial instruments. Per November 11, 2024, BlackRock, Inc. has adjusted its holding of shares to an equivalent of 23,180,630 shares, corresponding to 4.94% (previously 5.02%) of the total share capital attached to shares. The combined total of share capital attached to shares and share capital through financial instr...

18h / 46m 1 EN
 PRESS RELEASE
Free
NZYM B Novozymes A/S C...

Q3 update: Novonesis delivers strong Q3 results and now expects full-y...

Q3 update: Novonesis delivers strong Q3 results and now expects full-year organic sales growth at the upper end of 7-8% Following increasing demand in the first nine months of the 2024 financial year, Novonesis delivers 9% organic sales growth with a strong 11% organic sales growth in the third quarter. The strong performance has led Novonesis to now expect full-year organic sales growth to be at the upper end of the 7-8% range, and the adjusted EBITDA margin is confirmed to be between 35.5-36.5%. COPENHAGEN, Denmark – November 7, 2024. Novonesis delivers 9% organic sales growth, in the fir...

November 7, 2024 1 EN
 PRESS RELEASE
Free
NZYM B Novozymes A/S C...

Trading statement 9M 2024

Trading statement 9M 2024 Organic pro forma sales growth of 9%, including 11% in the third quarter. Full-year organic sales growth outlook now expected at the upper end of the 7-8% range and the adjusted EBITDA margin confirmed between 35.5-36.5%. Ester Baiget, President & CEO: “We continue to execute strongly across the business. Supportive, broad-based demand coupled with strong innovation and commercial focus drive higher market penetration. Novonesis’ biosolutions are increasingly requested by customers to make their products and processes healthier and more efficient, with less...

November 7, 2024 1 EN
 PRESS RELEASE
Free
NZYM B Novozymes A/S C...

Trading by management and close relations of management

Trading by management and close relations of management Announcement released on November 4, 2024 at 10:07:51 CET did not include PDF file. Please see the full announcement in the attached PDF file. Attachment

November 4, 2024 1 EN
 PRESS RELEASE
Free
NZYM B Novozymes A/S C...

Trading by management and close relations of management

Trading by management and close relations of management In accordance with article 19 in Regulation (EU) No 596/2014 of 16 April 2014 on market abuse (the Market Abuse Regulation) and commission delegated regulation (EU) 1052/2016 of 8 March 2016, Novozymes A/S, part of Novonesis Group reports the following transactions under ISIN DK0060336014, Novonesis (Novozymes) B shares under the symbol NSIS B. The released shares relate to the 2022 legacy Chr. Hansen restricted stock units (RSU) program. Please read the full announcement in PDF.

November 4, 2024 1 EN

ResearchPool Subscriptions

Get the most out of your insights

Get in touch